Summary:
In patients with type 2 diabetes and atherosclerotic cardiovascular disease,
tirzepatide was noninferior in reducing a composite of death from cardiovascular causes, myocardial infarction, or stroke compared to dulaglutide, though it was associated with gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes and established atherosclerotic cardiovascular disease. |
| Intervention | Once-weekly tirzepatide (doses as per SURPASS-CVOT trial protocol). |
| Comparison | Once-weekly dulaglutide (doses as per SURPASS-CVOT trial protocol). |
| Outcome | Tirzepatide was noninferior to dulaglutide for the composite outcome of cardiovascular death, myocardial infarction, or stroke. Tirzepatide treatment was associated with increased gastrointestinal adverse events. |
Clinical Context
Tirzepatide represents a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated superior glycemic control and weight loss compared to GLP-1 receptor agonists alone in prior trials. GLP-1 receptor agonists have established cardiovascular benefits in type 2 diabetes, reducing major adverse cardiovascular events in multiple outcome trials. The cardiovascular effects of GIP receptor agonism are less well characterized, and whether the dual agonist approach of tirzepatide provides equivalent cardiovascular protection compared to established GLP-1 receptor agonists requires dedicated outcomes evaluation. The SURPASS-CVOT trial addressed this question by directly comparing tirzepatide to dulaglutide, a GLP-1 receptor agonist with proven cardiovascular benefit demonstrated in the REWIND trial. This head-to-head comparison provides the evidence needed to understand tirzepatide’s cardiovascular profile relative to current standard of care incretin-based therapies.
Clinical Pearls
- Tirzepatide demonstrated cardiovascular noninferiority to dulaglutide, confirming that dual GIP/GLP-1 receptor agonism provides cardiovascular protection comparable to single GLP-1 receptor agonism.
- The composite outcome of cardiovascular death, myocardial infarction, and stroke was equivalent between treatments, supporting tirzepatide use in patients with established atherosclerotic cardiovascular disease.
- Gastrointestinal adverse events occurred more frequently with tirzepatide, consistent with its more potent metabolic effects and prior experience from the SURPASS glycemic control trials.
- The active comparator design using an agent with proven cardiovascular benefit provides stronger evidence than placebo-controlled trials for guiding treatment selection among incretin therapies.
Practical Application
Clinicians can prescribe tirzepatide with confidence for patients with type 2 diabetes and established cardiovascular disease, knowing that cardiovascular protection is comparable to dulaglutide. When selecting between these agents, the decision should consider the superior glycemic and weight reduction efficacy of tirzepatide against its higher gastrointestinal adverse event rates. For patients prioritizing maximal weight loss and glycemic control who can tolerate gastrointestinal symptoms, tirzepatide may be preferred. For patients with gastrointestinal sensitivity or those achieving adequate control with current GLP-1 receptor agonist therapy, continuing dulaglutide remains appropriate. Insurance coverage, cost, and availability may also influence agent selection given tirzepatide’s newer market status. The noninferiority finding supports both options as cardiovascularly protective in this high-risk population.
Broader Evidence Context
The SURPASS-CVOT trial represents a critical addition to the cardiovascular outcomes trial landscape for incretin-based therapies. Previous GLP-1 receptor agonist cardiovascular outcome trials demonstrated superiority versus placebo, but direct comparisons between agents have been limited. This trial’s active comparator design against a proven cardiovascular benefit agent sets a higher bar than traditional placebo-controlled noninferiority designs. The findings support that GIP receptor agonism combined with GLP-1 receptor agonism maintains cardiovascular protection, answering an important mechanistic question about this novel therapeutic approach. The results position tirzepatide alongside established GLP-1 receptor agonists for cardiovascular risk reduction in type 2 diabetes.
Study Limitations
- Noninferiority was demonstrated but superiority was not established, leaving open the question of whether tirzepatide might provide greater cardiovascular benefit than dulaglutide.
- The specific doses of tirzepatide and dulaglutide used were not detailed in the summary, limiting protocol comparison.
- Study duration and event rates were not specified, affecting interpretation of statistical power and clinical magnitude.
- Whether the gastrointestinal adverse events led to differential treatment discontinuation that could confound cardiovascular outcomes is not addressed.
- Cost-effectiveness comparing the agents was not evaluated despite potential significant cost differences.
Bottom Line
Tirzepatide is noninferior to dulaglutide for reducing major adverse cardiovascular events in type 2 diabetes patients with established atherosclerotic cardiovascular disease, though it causes more gastrointestinal side effects. Clinicians can select between these incretin therapies based on patient preferences and tolerability while maintaining confidence in cardiovascular protection.
Source: Stephen J Nicholls, et al. “Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.” Read article here.
